Chemkart India
Listing performance
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 07 Jul 2025 – 09 Jul 2025
- Listing date
- 14 Jul 2025
- Face value
- ₹10 per share
- Issue price
- ₹248 per share
- Lot size
- 600 shares
- Issue type
- Book Building issue
- Total issue size
- ₹80.08 Cr
- Market cap at offer price
- ₹300 Cr
- Promoter holding
- 100.00% → 73.28% pre-issue → post-issue
- ISIN
- INE0VWL01017
- Registrar
- Bigshare Services Pvt.Ltd.
- Lead managers
- Smart Horizon Capital Advisors Pvt.Ltd.
- Registered office
- Office No.403/404, 4th Floor, K.L.Accolade, 6th Road, TPS III, Santacruz (East), Maharashtra
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 9,11,400 | — | — |
| Market maker | 1,66,200 | — | — |
Application size
Minimum 600 shares per lot, in multiples, at ₹248
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 600 | ₹1,48,800 |
| S-HNI (min) | 2 | 1,200 | ₹2,97,600 |
| S-HNI (max) | 6 | 3,600 | ₹8,92,800 |
| B-HNI (min) | 7 | 4,200 | ₹10,41,600 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Valuation and performance
Valuation at offer price
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 25.54 | 20.05 |
| P/E (×) | 9.71 | 12.37 |
| Price to book (×) | 8.12 | — |
| Market cap | — | ₹300 Cr |
Key performance indicators
- Return on net worth
- 45.52%
- ROCE
- 49.00%
- Debt / equity
- 0.32
- PAT margin
- 12.00%
- EBITDA margin
- 16.12%
- NAV per share
- ₹56.10
- Price to book
- 8.12
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Chemkart India
Chemkart India Limited, incorporated on March 6, 2020, operates as a trading and processing company specializing in nutraceutical products and health supplements. The company was converted from a private limited entity to a public limited company on October 4, 2024. Based in Mumbai, Chemkart offers diverse captivated nutritional supplements and components across seven product categories: Amino Acids, Health Supplement, Herbal Extract, Nucleotide, Protein, Sports Nutrition, and Vitamin. The company earns revenue primarily through trading and processing these products for customers requiring custom blends. It maintains a warehouse facility with integrated processing and blending capabilities at Bhiwandi, Thane, covering 28,259.16 sq. ft., and operates from its registered office in Mumbai. The company is positioned to capitalize on growing awareness regarding nutritional needs in food products and intends to expand through backward integration by establishing a manufacturing facility through its wholly-owned subsidiary, Easy Raw Materials Private Limited.
Company Analysis
from DRHPChemkart India Limited is a one-stop provider of nutritional, health and sports supplement products offered across seven categories, serving the nutraceutical and health supplement industry through trading and processing of premium ingredients.
Chemkart India Limited, incorporated on March 6, 2020, operates as a trading and processing company specializing in nutraceutical products and health supplements. The company was converted from a private limited entity to a public limited company on October 4, 2024. Based in Mumbai, Chemkart offers diverse captivated nutritional supplements and components across seven product categories: Amino Acids, Health Supplement, Herbal Extract, Nucleotide, Protein, Sports Nutrition, and Vitamin. The company earns revenue primarily through trading and processing these products for customers requiring custom blends. It maintains a warehouse facility with integrated processing and blending capabilities at Bhiwandi, Thane, covering 28,259.16 sq. ft., and operates from its registered office in Mumbai. The company is positioned to capitalize on growing awareness regarding nutritional needs in food products and intends to expand through backward integration by establishing a manufacturing facility through its wholly-owned subsidiary, Easy Raw Materials Private Limited.
Objects of the Issue
- Financing the capital expenditure towards setting up of the Manufacturing Facility through investment in our Wholly-Owned Subsidiary (WOS) Company, Easy Raw Materials Private Limited ₹3,622.36 Lakhs p.98
- Repayment/prepayment of all or certain of our borrowings availed of by our Company ₹2,000.00 Lakhs p.98
- General Corporate Purpose [●] Lakhs (not to exceed 15% of amount raised or ₹10 Crores, whichever is less) p.98
Issue Structure
- Total Issue
- Up to 32,30,000 Equity Shares aggregating up to ₹[●] Lakhs
- Fresh Issue
- Up to 26,00,000 Equity Shares aggregating up to ₹[●] Lakhs
- Offer for Sale
- Up to 6,30,000 Equity Shares aggregating up to ₹[●] Lakhs
- Price Band
- ₹[●] per Equity Share (Floor Price: ₹[●]; Cap Price: ₹[●])
- Lot Size
- [●] Equity Shares and in multiples of [●] Equity Shares thereafter
- Face Value
- ₹10/- per Equity Share
Business Model
Chemkart operates as a nutraceutical trading and processing company, procuring raw materials from domestic and international suppliers (predominantly China at 81.46% of total purchases for the period ended September 30, 2024) and selling finished products to customers. The company generates revenue from the sale of traded products and custom processing services where it blends or processes materials per customer requirements. The company maintains working inventory to fulfill customer orders and manages distribution primarily through direct customer relationships rather than long-term contracts, relying instead on purchase orders for individual transactions.
Business Segments
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Mr. Ankit Shailesh Mehta | Promoter/Selling Shareholder | 50.00% | [●]% |
| Ms. Parul Shailesh Mehta | Promoter/Selling Shareholder | 50.00% | [●]% |
| Mr. Shailesh Vinodrai Mehta | Promoter | Negligible | [●]% |
Leadership
Auto-extracted from the company's DRHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official DRHP before relying on it.